BioNotebook: Targacept gone in reverse merger with Catalyst, plus five other deals
This article was originally published in Scrip
Executive Summary
After a string of failures, Winston-Salem, North Carolina-based Targacept and its neuronal nicotinic receptor (NNR) therapeutics will be replaced by engineered human proteases for hemophilia and complement-mediated disorders in a reverse merger with privately-held Catalyst Biosciences in South San Francisco.
You may also be interested in...
Grifols Expansion Plans Include Biotech Equity, New US Manufacturing Facilities
Taking a 20% equity stake in US biotech Singulex and planning to build new manufacturing facilities in the US and Europe reflect the global expansion plans of Spain’s plasma product manufacturer Grifols, the third-largest in the world.
Kite Readies A Second CAR-T For Filing As CD19 Competition Grows
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Need a specific report? 1000+ reports available
Buy Reports